Regulatory
How we handle claims while the product is in development
Partners need to know what we will and will not say. A feed product aimed at a disease-resilience research objective has to keep a hard line between that objective and a marketable claim. This page is that line.
Statement of position
The formulation described on this site is in development. Its biological performance has not been established through controlled validation. This program makes no claim that the formulation prevents, treats, mitigates, cures, or reduces the incidence or severity of highly pathogenic avian influenza or any other disease, and makes no claim regarding mortality, viral load, viral shedding, or clinical outcomes. The product is not manufactured for sale, marketed, or available for purchase.
Why classification is treated as an open question
The final regulatory classification of the product and the scope of any permissible commercial claim will depend on ingredient status, intended use as represented, the evidence generated during validation, labeling, and the applicable federal and state requirements. This program does not assume that the product is categorically regulated only as conventional feed.
That is a deliberate position. Under the U.S. framework, intended use as represented by the person marketing an article is central to how the article is regulated. An additive positioned around a disease objective may fall outside the feed pathway depending on the claims made. The program therefore resolves classification and claim scope before commercial representation, not after.
The framework being addressed
| Authority or framework | Relevance to this program |
|---|---|
| FDA Center for Veterinary Medicine | Federal oversight of animal food and animal drugs. The program's regulatory work stream includes ingredient-status review and assessment of applicable CVM requirements, including the boundary between a nutritional representation and a drug claim, with CVM guidance sought where appropriate. |
| AAFCO ingredient definitions | Ingredient-definition and labeling conventions relied upon by state feed-control officials. Each component's definitional status and permissible label representation is assessed before commercial use. |
| State feed-control authorities | Product registration, labeling review, and claim review operate at state level. Distribution requires compliance in each state of sale. |
| 21 C.F.R. § 530.41(d) | Prohibits extra-label use of adamantanes and neuraminidase inhibitors in chickens, turkeys, and ducks. Cited here because it is part of why a non-pharmaceutical, nutrition-based line of investigation is being pursued at all. |
| Biosafety and USDA authorization | Any work involving live highly pathogenic avian influenza virus is conducted exclusively in facilities operating at the required biosafety level, under approved institutional protocols and applicable USDA authorization. |
Sequence governing any future claim
No disease-related representation will be made commercially unless and until each of the following has occurred, in order:
- Formulation and analytical work establishes a standardized, reproducible product with defined marker specifications and demonstrated stability through feed manufacturing and storage.
- Controlled biological evaluation is conducted in appropriately qualified facilities against predefined safety, tolerance, and response endpoints, with results analyzed statistically.
- Regulatory classification is determined and a lawful claim set is defined that is supported by the data actually generated, and no broader.
- Labeling and any required registration is completed for each jurisdiction of sale.
What this means if you mill, formulate, or raise birds
If you are a producer, feed manufacturer, or nutritionist looking at this work, please read the progress page before drawing conclusions. Any participation discussed at this stage concerns research and evaluation activity, not the supply of a product for disease-prevention use.
Corrections
If any statement on this site appears to exceed the position set out above, or appears to constitute a claim, that is an error and will be corrected promptly. Please write to research@neuranextsolutions.com.